{"id":"W4236850195","doi":"10.1017/cjn.2019.120","title":"P.020 Avelumab in newly diagnosed glioblastoma multiforme-the SEJ study","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Avelumab; Temozolomide; Medicine; Radiation therapy; Internal medicine; Adverse effect; Interim analysis; Oncology; Incidence (geometry); Clinical trial; Immunotherapy; Nivolumab; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009598347,0.0003633602,0.000736037,0.0001873494,0.0002102723,0.0006751923,0.000318489,0.0005600463,0.002590132],"category_scores_gemma":[0.0005761772,0.0001745135,0.0008822448,0.0003199482,0.000224416,0.0004422695,0.0001974957,0.0009918573,0.0005138512],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003442601,"about_ca_system_score_gemma":0.0007706684,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001116084,"about_ca_topic_score_gemma":0.002464867,"domain_scores_codex":[0.9997821,0.00008909459,0.00001638865,0.00003276876,0.00003777179,0.00004181865],"domain_scores_gemma":[0.9995494,0.00006807842,0.00009433824,0.00004002158,0.00005706541,0.000190947],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5664104,0.01618663,0.1537933,0.003300469,0.008235604,0.001644396,0.0003252783,0.000961294,0.02668652,0.0008154698,0.01300746,0.2086333],"study_design_scores_gemma":[0.2635002,0.234918,0.4575485,0.0003622902,0.006609794,0.001880922,0.0002820693,0.001532248,0.003965364,0.0007065571,0.02861909,0.00007492863],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876333,0.006532552,0.0001556086,0.000595402,0.0001556953,0.0003711812,0.001211095,0.00001971147,0.003325534],"genre_scores_gemma":[0.9897088,0.003924683,0.0003609135,0.0007072673,0.0002501787,0.0002863129,0.001674201,0.00001367546,0.003074027],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002590132,"threshold_uncertainty_score":0.008664787,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02425424905372213,"score_gpt":0.2782407022711403,"score_spread":0.2539864532174182,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}